ORENCIA Drug Insight and Market Forecast - 2032

“ORENCIA Drug Insight and Market Forecast - 2032” report provides comprehensive insights about ORENCIA for Rheumatoid Arthritis in the 7MM. A detailed picture of the ORENCIA for Rheumatoid Arthritis in the 7MM, i.e., United States, EU4 (Germany, France, Italy, and Spain), and the United Kingdom, and Japan for the study period 2019-2032 is provided in this report along with a detailed description of the ORENCIA for Rheumatoid Arthritis. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the ORENCIA market forecast, analysis for Rheumatoid Arthritis in the 7MM, descriptive analysis such as SWOT, analysts' views, comprehensive overview of market competitors, and brief about emerging therapies in Rheumatoid Arthritis.

Drug Summary

ORENCIA is an immunomodulator that disrupts the continuous cycle of T-cell activation that characterizes RA. It is a selective T cell co stimulation modulator. ORENCIA is a soluble fusion protein that consists of the extracellular domain of human cytotoxic T-lymphocyte associated antigen 4 (CTLA-4) linked to the modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1). Abatacept is produced by recombinant DNA technology in a mammalian cell expression system. The apparent molecular weight of abatacept is 92 kilo Daltons. ORENCIA is the only RA biologic that offers three administration options: IV infusion, prefilled syringe and auto injector. ORENCIA for Injection is a lyophilized powder for intravenous infusion.

BMS and Ono also jointly develop and commercialize ORENCIA in Japan. BMS is responsible for the order fulfillment and distribution of the intravenous formulation and Ono is responsible for the subcutaneous formulation. Both formulations are jointly promoted by both parties with assigned customer accounts and BMS is responsible for the product supply. ORENCIA experienced a reimbursement decreases in July 2021 due to new ASP calculation methodology.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the ORENCIA description, mechanism of action, dosage and administration, research and development activities in Rheumatoid Arthritis.
• Elaborated details on ORENCIA regulatory milestones and other development activities have been provided in this report.
• The report also highlights the ORENCIA research and development activity in Rheumatoid Arthritis details across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around ORENCIA.
• The report contains forecasted sales of ORENCIA for Rheumatoid Arthritis till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Rheumatoid Arthritis.
• The report also features the SWOT analysis with analyst views for ORENCIA in Rheumatoid Arthritis.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by the research team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

ORENCIA Analytical Perspective

In-depth ORENCIA Market Assessment

This report provides a detailed market assessment of ORENCIA in Rheumatoid Arthritis in the 7MM, i.e., United States, EU4 and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.

ORENCIA Clinical Assessment

The report provides the clinical trials information of ORENCIA for Rheumatoid Arthritis covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

• In the coming years, the market scenario for Rheumatoid Arthritis is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence ORENCIA dominance.
• Other emerging products for Rheumatoid Arthritis are expected to give tough market competition to ORENCIA and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of ORENCIA in Rheumatoid Arthritis.
• This in-depth analysis of the forecasted sales data of ORENCIA from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the ORENCIA in Rheumatoid Arthritis.

 

Key Questions Answered

• What is the product type, route of administration and mechanism of action of ORENCIA?
• What is the clinical trial status of the study related to ORENCIA in Rheumatoid Arthritis and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the ORENCIA development?
• What are the key designations that have been granted to ORENCIA for Rheumatoid Arthritis?
• What is the forecasted market scenario of ORENCIA for Rheumatoid Arthritis?
• What are the forecasted sales of ORENCIA in the 7MM, including the United States, Europe, and Japan?
• What are the other emerging products available in Rheumatoid Arthritis and how are they giving competition to ORENCIA for Rheumatoid Arthritis?
• Which are the late-stage emerging therapies under development for the treatment of Rheumatoid Arthritis?

This product will be delivered within 2 business days.